首頁 > 市場調查報告書 > 製藥

神經疾病

帕金森氏症藥物市場規模、佔有率和成長分析（按藥物類別、給藥途徑、年齡層和地區分類）—產業預測（2026-2033 年）

市場調查報告書

商品編碼

1901951

帕金森氏症藥物市場規模、佔有率和成長分析（按藥物類別、給藥途徑、年齡層和地區分類）—產業預測（2026-2033 年）

Parkinson's Disease Drug Market Size, Share, and Growth Analysis, By Drug Class (Decarboxylase Inhibitors, Dopamine Agonists), By Administration (Oral, Injection), By Age, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月23日 | 出版商:

SkyQuest | 英文 165 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

預計到 2024 年，全球帕金森氏症藥物市場規模將達到 50.9 億美元，到 2025 年將達到 56.3 億美元，到 2033 年將達到 126 億美元，在預測期（2026-2033 年）內，複合年成長率為 10.6%。

由於帕金森氏症這種神經系統疾病的盛行率不斷上升，導致全球超過1000萬人患病，並嚴重損害運動功能，因此帕金森氏症治療市場正經歷顯著成長。多巴胺分泌減少會導致一系列嚴重的症狀，從而催生了對有效治療方法的需求。市場擴張的動力來自對聯合治療、創新長效藥物以及促進神經移植的基因療法等先進療法的需求，並得到了政府資金的支持。此外，人口成長、醫療基礎設施的改善、持續的研發投入以及不斷成長的醫療支出等因素也為市場提供了持續的機會。同時，現有藥物專利到期以及大量新興治療方法的湧現也為市場參與者帶來了有利的前景。

全球帕金森氏症藥物市場促進因素

全球帕金森氏症藥物市場的成長受到人口老化和神經系統疾病發病率上升的顯著影響。隨著帕金森氏症確診患者人數的持續增加，對有效治療方法方法的需求也隨之增加。這種日益成長的醫療干預需求是推動市場發展的關鍵因素。此外，隨著人們對該疾病認知的提高和藥物研發的進步，滿足帕金森氏症患者需求的迫切需求預計將進一步推動市場規模的顯著擴張。

限制全球帕金森氏症藥物市場的因素

帕金森氏症治療成本的不斷攀升預計將阻礙全球帕金森氏症治療市場的成長。患者、其家庭和醫療保健系統面臨的經濟負擔是一項重大挑戰，限制了患者獲得必要治療的機會，並成為市場擴張的障礙。隨著高昂成本的日益凸顯，醫療資源整體壓力不斷增加，病患照護環境也更加複雜。因此，這一經濟障礙仍然是限制市場成長的主要因素，並持續為帕金森氏症治療領域的相關人員帶來挑戰。

全球帕金森氏症治療市場趨勢

全球帕金森氏症藥物市場呈現顯著上升趨勢，這主要得益於研發投入的不斷增加，以開發創新治療方法。政府機構和私人企業的快速注資為專注於帕金森氏症新治療方法研發的製藥公司創造了充滿活力的市場環境。這些努力不僅豐富了潛在藥物的研發管線，也為先進治療方法的開發鋪平了道路，進一步提升了市場成長潛力。因此，持續研發有效帕金森氏症藥物的努力預計將顯著改變該市場的格局。

AbbVie Inc.（USA）
Novartis AG（Switzerland）
Teva Pharmaceutical Industries Ltd.（Israel）
UCB SA（Belgium）
GlaxoSmithKline plc（UK）
Merck & Co., Inc.（USA）
Boehringer Ingelheim（Germany）
Lundbeck A/S（Denmark）
Acadia Pharmaceuticals Inc.（USA）
Sun Pharmaceutical Industries Ltd.（India）
Amneal Pharmaceuticals, Inc.（USA）
Supernus Pharmaceuticals, Inc.（USA）
Kyowa Kirin Co., Ltd.（Japan）
Orion Corporation（Finland）
Neurocrine Biosciences, Inc.（USA）
Acorda Therapeutics, Inc.（USA）
Ipsen SA（France）
Luye Pharma Group（China）
NeuroDerm Ltd.（Israel）（acquired by Mitsubishi Tanabe Pharma）
Revance Therapeutics, Inc.（USA）

結論與建議

簡介目錄

Product Code: SQSG35I2024

Global Parkinson'S Disease Drug Market size was valued at USD 5.09 Billion in 2024 and is poised to grow from USD 5.63 Billion in 2025 to USD 12.6 Billion by 2033, growing at a CAGR of 10.6% during the forecast period (2026-2033).

The Parkinson's disease drug market is witnessing significant growth due to the increasing prevalence of this neurological condition, which affects over 10 million people globally and impairs movement. The decline in dopamine production leads to various debilitating symptoms, creating a demand for effective treatments. The market's expansion is driven by the need for combination therapies that enhance neural transplantation, innovative long-acting medications, and advancements like gene therapy, bolstered by government funding. Furthermore, factors such as a growing population, improved healthcare infrastructure, ongoing research and development, and rising healthcare expenditures position the market for continued opportunities. Additionally, the patent expirations of established drugs and a strong pipeline of emerging therapies present lucrative prospects for market players.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Parkinson'S Disease Drug market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Parkinson'S Disease Drug Market Segments Analysis

Global Parkinson'S Disease Drug Market is segmented by drug class, administration, age and region. Based on drug class, the market is segmented into decarboxylase inhibitors, dopamine agonists, COMT inhibitors, MAO-b inhibitors and others. Based on administration, the market is segmented into oral, injection and transdermal. Based on age, the market is segmented into < 50 years and > 50 years. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Parkinson'S Disease Drug Market

The growth of the global Parkinson's Disease drug market is significantly influenced by the escalating aging population and the rising incidence of neurological disorders. As the number of individuals diagnosed with Parkinson's disease continues to climb, there is a corresponding surge in the demand for effective treatments and therapies. This heightened need for medical interventions plays a crucial role in propelling the market forward. Furthermore, as awareness of the disease increases and advancements in drug development are made, the market is poised for substantial expansion, driven by the urgent requirement to address the needs of those affected by this debilitating condition.

Restraints in the Global Parkinson'S Disease Drug Market

The escalating costs associated with treating Parkinson's disease are expected to hinder the growth of the global market for Parkinson's disease drugs. The financial burden placed on patients, their families, and healthcare systems presents a significant challenge, limiting access to necessary treatments and creating barriers to market expansion. As these high expenses become more pronounced, they contribute to the overall strain on resources, further complicating the care landscape for those affected. Consequently, this financial hurdle remains a primary factor restraining market growth and poses ongoing challenges for stakeholders within the Parkinson's disease treatment sector.

Market Trends of the Global Parkinson'S Disease Drug Market

The Global Parkinson's Disease Drug market is witnessing a significant upward trend driven by heightened investment in research and development initiatives aimed at innovative treatment options. This surge in funding from both governmental bodies and private corporations is fostering a dynamic environment for pharmaceutical companies focused on crafting novel therapies for Parkinson's disease. These efforts are not only enhancing the pipeline of potential medications but are also paving the way for advanced treatment methodologies, thereby amplifying the market's growth potential. As a result, the ongoing commitment to developing effective Parkinson's disease drugs is set to significantly shape the landscape of this market.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis

Global Parkinson's Disease Drug Market Size by Drug Class & CAGR (2026-2033)

Market Overview
Decarboxylase Inhibitors
Dopamine Agonists
COMT Inhibitors
MAO-B Inhibitors
Others

Global Parkinson's Disease Drug Market Size by Administration & CAGR (2026-2033)

Market Overview
Oral
Injection
Transdermal

Global Parkinson's Disease Drug Market Size by Age & CAGR (2026-2033)

Market Overview
< 50 Years
>50 Years

Global Parkinson's Disease Drug Market Size & CAGR (2026-2033)

North America (Drug Class, Administration, Age)
- US
- Canada
Europe (Drug Class, Administration, Age)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Drug Class, Administration, Age)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Drug Class, Administration, Age)
- Brazil
- Rest of Latin America
Middle East & Africa (Drug Class, Administration, Age)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

AbbVie Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
UCB S.A. (Belgium)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boehringer Ingelheim (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lundbeck A/S (Denmark)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Acadia Pharmaceuticals Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sun Pharmaceutical Industries Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amneal Pharmaceuticals, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Supernus Pharmaceuticals, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Kyowa Kirin Co., Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Orion Corporation (Finland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Neurocrine Biosciences, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Acorda Therapeutics, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ipsen S.A. (France)
- Company OvervSiew
- Business Segment Overview
- Financial Updates
- Key Developments
Luye Pharma Group (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
NeuroDerm Ltd. (Israel) (acquired by Mitsubishi Tanabe Pharma)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Revance Therapeutics, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments